Sugi Predict

Sugi Predict / Compounds / SCHEMBL5377638

SCHEMBL5377638

SCHEMBL5377638

Nc1ccc(OCc2ccccc2)cc1C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 2/20 0.58
▸ NR4A2 P43354 2/20 0.57
▸ PTGES O14684 1/20 0.55
▸ PARP10 Q53GL7 1/20 0.55
▸ MAOB P27338 3/20 0.55
▸ NR4A1 P22736 1/20 0.54
▸ NR4A3 Q92570 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ MAPT P10636 3/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ SMPD1 P17405 1/20 0.52
▸ GAA P10253 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MRGPRX4 Q96LA9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474131 0.88 NR4A2 (0.57) SRD5A2NR4A2PARP10MAOBNR4A1
SCHEMBL28536118 0.87 MEN1 (0.55) SRD5A2NR4A2PTGESPARP10MAOB
SCHEMBL4930554 0.87 PARP10 (0.60) NR4A2PARP10MAOBNR4A1NR4A3
SCHEMBL7914507 0.85 SRD5A2 (0.66) SRD5A2NR4A2PTGESPARP10MAOB
SCHEMBL8564043 0.85 SRD5A2 (0.65) SRD5A2NR4A2MAOBALDH1A1MAPT
SCHEMBL26863 0.84 MAOB (0.71) SRD5A2NR4A2PTGESPARP10MAOB
SCHEMBL29481015 0.84 MAOB (0.71) SRD5A2NR4A2PTGESPARP10MAOB
SCHEMBL5119495 0.84 SRD5A2 (0.59) SRD5A2NR4A2PTGESPARP10MAOB
SCHEMBL15589447 0.83 MAOB (0.51) SRD5A2NR4A2PARP10MAOBNR4A1
SCHEMBL136203 0.83 ALDH1A1 (0.56) PARP10MAOBALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220771-B2 Methods of using indazole derivatives as JNK inhibitors SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-22 — — US disclosed
US-7211594-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-01 — — US disclosed
US-7208513-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-04-24 — — US disclosed
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds SIGNAL PHARMACEUTICALS, LLC 2007-03-15 — — US disclosed
EP-1618093-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS Signal Pharmaceuticals LLC (US) 2006-01-25 — — EP disclosed
US-6897231-B2 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. (US) 2005-05-24 — — US disclosed
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SINGNAL PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 — — US disclosed
WO-2004094388-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2004-11-04 — — WO disclosed
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 — — US disclosed
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. 2004-04-22 — — US disclosed
EP-1313711-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2003-05-28 — — EP disclosed
WO-2002010137-A9 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARM INC (US) 2003-02-06 — — WO disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 — — US disclosed
WO-2002010137-A2 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 SRD5A2 2886/4885NR4A2 967/4885PTGES 521/4885
US-20040077877-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 SRD5A2 2761/4885NR4A2 1459/4885PTGES 1481/4885
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds BCL9, MCL1, INMT SRD5A2 1743/4885NR4A2 3085/4885PTGES 3753/4885
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 SRD5A2 3472/4885NR4A2 1420/4885PTGES 1186/4885
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 SRD5A2 2761/4885NR4A2 1459/4885PTGES 1481/4885
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R SRD5A2 2563/4885NR4A2 1876/4885PTGES 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.